Takeda's azilsartan approved in the US
This article was originally published in Scrip
The US FDA has approved Takeda's angiotensin II antagonist Edarbi (azilsartan medoxomil) for the treatment of hypertension in adults, for use either alone or in combination with other antihypertensives. The standard dose is 80mg once daily, although a starting dose of 40mg/day may be appropriate for patients on high doses of diuretics.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.